Forte Biosciences (FBRX) Free Cash Flow Growth (5y) (2021 - 2026)
Forte Biosciences (FBRX) Free Cash Flow Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn |
| 10 | Forte Biosciences | 1.36 Bn | 1.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.07% |
| Dec 31, 2025 | -34.09% |
| Sep 30, 2025 | -12.68% |
| Jun 30, 2025 | -20.16% |
| Mar 31, 2025 | -29.45% |
| Dec 31, 2024 | -68.37% |
| Sep 30, 2024 | -69.05% |
| Jun 30, 2024 | -18.82% |
| Mar 31, 2024 | 17.73% |
| Dec 31, 2023 | 5.00% |
| Sep 30, 2023 | -54.89% |
| Jun 30, 2023 | 13.94% |
| Mar 31, 2023 | 16.41% |
| Dec 31, 2022 | 21.44% |
| Sep 30, 2022 | 22.84% |
| Jun 30, 2022 | 28.63% |
| Mar 31, 2022 | 23.61% |
| Dec 31, 2021 | 14.32% |
| Sep 30, 2021 | 8.74% |
| Jun 30, 2021 | 13.43% |